JP2006523238A5 - - Google Patents

Download PDF

Info

Publication number
JP2006523238A5
JP2006523238A5 JP2006509820A JP2006509820A JP2006523238A5 JP 2006523238 A5 JP2006523238 A5 JP 2006523238A5 JP 2006509820 A JP2006509820 A JP 2006509820A JP 2006509820 A JP2006509820 A JP 2006509820A JP 2006523238 A5 JP2006523238 A5 JP 2006523238A5
Authority
JP
Japan
Prior art keywords
ring
compound according
optionally substituted
atoms
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006509820A
Other languages
English (en)
Japanese (ja)
Other versions
JP4895806B2 (ja
JP2006523238A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/010858 external-priority patent/WO2004092196A2/en
Publication of JP2006523238A publication Critical patent/JP2006523238A/ja
Publication of JP2006523238A5 publication Critical patent/JP2006523238A5/ja
Application granted granted Critical
Publication of JP4895806B2 publication Critical patent/JP4895806B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006509820A 2003-04-09 2004-04-08 Ｔｉｅ−２モジュレータと使用方法 Expired - Fee Related JP4895806B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46144603P 2003-04-09 2003-04-09
US60/461,446 2003-04-09
PCT/US2004/010858 WO2004092196A2 (en) 2003-04-09 2004-04-08 Tie-2 modulators and methods of use

Publications (3)

Publication Number Publication Date
JP2006523238A JP2006523238A (ja) 2006-10-12
JP2006523238A5 true JP2006523238A5 (https=) 2007-06-28
JP4895806B2 JP4895806B2 (ja) 2012-03-14

Family

ID=33299811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509820A Expired - Fee Related JP4895806B2 (ja) 2003-04-09 2004-04-08 Ｔｉｅ−２モジュレータと使用方法

Country Status (6)

Country Link
US (1) US7763627B2 (https=)
EP (1) EP1610774A4 (https=)
JP (1) JP4895806B2 (https=)
AU (2) AU2004230928B2 (https=)
CA (1) CA2520323C (https=)
WO (1) WO2004092196A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2564355C (en) 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
KR20060079121A (ko) * 2004-12-31 2006-07-05 에스케이케미칼주식회사 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
ES2599458T3 (es) * 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
WO2011036074A1 (en) 2009-09-24 2011-03-31 Basf Se Aminoquinazoline compounds for combating invertebrate pests
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
BR112014007310A2 (pt) 2011-09-27 2017-04-04 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
KR102215272B1 (ko) * 2012-09-28 2021-02-15 이그니타, 인코포레이티드 비정형 단백질 키나제 c의 아자퀴나졸린 억제제
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
WO2015112739A1 (en) * 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
EP3226868A4 (en) 2014-12-05 2018-08-15 Subramaniam Ananthan Novel quinazolines as biogenic amine transport modulators
CA2969839A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Heterocyclic compounds as biogenic amine transport modulators
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
WO2017216726A1 (en) 2016-06-13 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of dnmt1
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
US11254654B2 (en) * 2017-06-30 2022-02-22 The University Of North Carolina At Chapel Hill Heterochromatin gene repression inhibitors
EP3867253A4 (en) * 2018-10-16 2022-05-18 Ikena Oncology, Inc. Indole ahr inhibitors and uses thereof
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
US20230339866A1 (en) * 2020-02-04 2023-10-26 TroBio Therapeutics Pty Ltd Quinazoline compounds and the use thereof in the treatment of cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340260A (en) 1962-12-03 1967-09-05 Ciba Geigy Corp 4-amino-pyrimidines
FR2263750A1 (en) * 1974-03-12 1975-10-10 Delalande Sa N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc.
US4306065A (en) * 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
DE19904710A1 (de) * 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2001036392A1 (en) * 1999-11-17 2001-05-25 Dainippon Pharmaceutical Co., Ltd. [5-chloro-6-phenyl-2-(4-trifluoromethylphenyl)-4-pyrimidinylamino]acetamide derivatives, process for producing the same, medicinal compositions containing the same and intermediate of these compounds
HK1050319B (en) * 1999-12-02 2007-04-04 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
KR100774855B1 (ko) * 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
WO2002022605A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004509876A (ja) * 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４−アミノ−キナゾリン
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
CA2433090A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
WO2002062767A1 (en) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives
UY27224A1 (es) * 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
WO2003026661A1 (fr) * 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
ATE466581T1 (de) * 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
WO2004030672A1 (en) * 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
GB0301016D0 (en) * 2003-01-16 2003-02-19 Univ London Treatment of benign prostatic hyperplasia
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
DE602004014347D1 (de) * 2003-03-12 2008-07-24 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren

Similar Documents

Publication Publication Date Title
JP2006523238A5 (https=)
RU2345996C1 (ru) Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
JP2008525526A5 (https=)
RU2386622C2 (ru) Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы
JP2015143283A5 (https=)
JP2010506942A5 (https=)
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
JP2016505012A5 (https=)
JP2007510665A5 (https=)
JP2020536863A5 (https=)
JP2014051526A5 (https=)
JP2008525417A5 (https=)
WO2008057862A3 (en) MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
JP2013528180A5 (https=)
RU2007124545A (ru) Производные [4-(гетероарил)пиперазин-1-ил]-(2,5-замещенный фенил)метанона в качестве ингибиторов переносчика глицина-1 (glyt-1) для лечения неврологических и психоневрологических заболеваний
JP2013509392A5 (https=)
RU2013141274A (ru) Содержащие фосфор соединения в качестве ингибиторов протеинкиназ
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
RU2012103460A (ru) НОВЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-1Н-ИМИДАЗО{1,2-a}ПИРИМИДИН-5-ОНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ В ФАРМАЦИИ
JP2005538944A5 (https=)
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
AR083832A1 (es) DERIVADOS DE TETRAHIDROPIRIDO[3,2-F][1,4]OXAZEPIN-8-AMINA PARA EL TRATAMIENTO DE ENFERMEDADES Ab-RELACIONADAS
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina